Evidence map›Paper›PMID 41583478›Full record

ArticleFrontiers in immunology2025

Risk factors for cancer and the importance of screening in adult recipients of living-donor kidney transplant.

Takahisa Hiramitsu, Yuki Shimamoto, Tomoki Himeno, Yuki Hasegawa, Kenta Futamura, Manabu Okada, Yutaka Matsuoka, Norihiko Goto, Toshihiro Ichimori, Shunji Narumi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Takahisa HiramitsuDepartment of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Yuki ShimamotoDepartment of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Tomoki HimenoDepartment of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Yuki HasegawaDepartment of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Kenta FutamuraDepartment of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Manabu OkadaDepartment of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Yutaka MatsuokaDepartment of Renal Transplant Surgery, Masuko Memorial Hospital, Nagoya, Japan.
Norihiko GotoDepartment of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Toshihiro IchimoriDepartment of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Shunji NarumiDepartment of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Takaaki KobayashiDepartment of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Japan.
Kazuharu UchidaDepartment of Renal Transplant Surgery, Masuko Memorial Hospital, Nagoya, Japan.
Yoshihiko WataraiDepartment of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The incidence of cancer after kidney transplantation (KT) increases owing to the use of immunosuppressive (IS) medications, which may lead to death with a functioning graft (DWFG) and reduced long-term graft survival. However, the effect of IS medications, including their blood levels, on cancer development before graft failure remains underexplored. Methods: This single-center retrospective cohort study involved 1274 living-donor KTs performed between January 2008 and December 2021. Cancer was diagnosed in 141 recipients before graft failure. DWFG and mortality-free survival were compared between recipients with and those without cancer before graft failure. Multivariable Cox regression analysis was used to identify risk factors for cancer. Trough levels of IS medications (calcineurin inhibitors and mycophenolate mofetil) were compared between recipients with and those without cancer. The effect of cancer detection (screening, incidental, or symptomatic) on DWFG was also evaluated. Results: DWFG and recipient mortality events were more common in the cancer group than in the non-cancer group. A significant risk factor for cancer was older recipient age ( Discussion: IS medication level was not a significant risk factor for cancer before graft failure. Nevertheless, cancer risk after KT significantly increased both DWFG and recipient mortality rates. Cancer screening may help reduce the incidence of DWFG and recipient mortality associated with cancer.

Indexed as

Kidney TransplantationLiving DonorsNeoplasmsAdultEarly Detection of CancerFemaleGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsImmunosuppressive Agentscancerdeath with a functioning graftimmunosuppressive medicationsliving-donor kidney transplantationtrough levels

Identifiers

PMID41583478
PMCPMC12827106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.